Newsletter Tool

Today's Rundown

Physician poll finds ultralong-acting regimens and home administration could transform HIV market
Oral prolonged-release ketamine advances after COVID-disrupted trial
In a first, FDA approves topical sirolimus for rare disease lesions
Genprex pairs gene therapy delivery tech with Keytruda in lung cancer trial
Antares, Lipocine expand testosterone therapy offerings with FDA nod for a new, oral med for hypogonadism

Featured Story

Physician poll finds ultralong-acting regimens and home administration could transform HIV market

By Nick Paul Taylor

Ultralong-acting regimens and home administration could rapidly shift the HIV market away from daily orals as the sector enters its “last cycle of innovation,” according to physicians surveyed by analysts at Jefferies.

Oral prolonged-release ketamine advances after COVID-disrupted trial

By Nick Paul Taylor

HMNC Brain Health and Develco Pharma are forging ahead with development of oral prolonged-release ketamine after seeing a “positive trend” in treatment-resistant depression, with a midphase study slated to start in the second quarter.

In a first, FDA approves topical sirolimus for rare disease lesions

By Nick Paul Taylor

Nobelpharma America has become the first company to win FDA approval for a topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC). The approval covers a topical gel formulation of sirolimus, a mTOR inhibitor also known as rapamycin.

Genprex pairs gene therapy delivery tech with Keytruda in lung cancer trial

By Nick Paul Taylor

Genprex has begun testing a drug candidate based on its systemic gene therapy delivery platform in combination with Merck’s Keytruda. The phase 1/2 clinical trial marks the start of Genprex’s effort to determine whether a delivery system based on opposing electrical charges can help improve the efficacy of the checkpoint inhibitor in patients with late-stage non-small cell lung cancer.

Antares, Lipocine expand testosterone therapy offerings with FDA nod for a new, oral med for hypogonadism

By Kevin Dunleavy

Antares and development partner Lipocine have gained FDA approval for Tlando, an oral testosterone replacement therapy for hypogonadism. The twice-daily oral drug is an alternative to Antares' Xyosted, a weekly injected TRT, which has been on the market for four years.

Whitepaper: Oncology Market Outlook: Key Trends to Watch

Sponsored by: Blue Matter, strategic consultants in the life sciences

What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market.

Whitepaper: Uncovering the hidden value of quality in chemical supply

eBook: Leveraging Clinical Data for Study Success

Sponsored by: Medidata, a Dassault Systèmes company

The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates.